Cutler Group’s UroGen Pharma URGN Stock Holding History

Cutler Group’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-400	Closed	-$6.42K	–	4348
2023 Q2	$4K	Buy	+400	New	+$4.41K	﹤0.01%	2771
2022 Q4	–	Sell	-500	Closed	-$4.74K	–	5264
2022 Q3	$4K	Buy	+500	New	+$4.14K	﹤0.01%	3865
2020 Q4	–	Sell	-3,500	Closed	-$67K	–	5516
2020 Q3	$67K	Sell	3,500 -2,473	-41%	-$56K	﹤0.01%	1593
2020 Q2	$156K	Buy	+5,973	New	+$146K	0.01%	1014

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Cutler Group's URGN Position: Q3 2023 in Review

Cutler Group sold out of UroGen Pharma (URGN) in Q3 2023, closing a stake of 400 shares — an estimated $6.42K sold.

Cutler Group first reported a position in URGN in Q2 2020 and held it in 4 quarters. The position peaked at $156K in Q2 2020. 101 funds tracked by Wall St. Rank hold URGN as of Q3 2023.

Cutler Group reported no remaining UroGen Pharma position as of Q3 2023 after selling out during the quarter.
Cutler Group sold 400 UroGen Pharma shares in Q3 2023, an estimated $6.42K.
Cutler Group first reported a position in UroGen Pharma in Q2 2020 and held it in 4 quarters.
Cutler Group's UroGen Pharma position peaked at $156K in Q2 2020.
101 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2023.

Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.